Form 4: Oramed CSO Miriam Kidron Granted 119,558 RSUs

Oramed Pharmaceuticals' Chief Scientific Officer, Miriam Kidron, received a grant of 119,558 Restricted Stock Units, vesting quarterly starting April 2026.

Summary

• Miriam Kidron, Director and Chief Scientific Officer of Oramed Pharmaceuticals Inc. (ORMP), was granted 119,558 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was March 17, 2026.
• Each RSU represents the right to receive one share of Oramed common stock, with a par value of $0.012 per share.
• The RSUs will vest ratably in 8 quarterly installments, commencing on April 1, 2026.
• Following this transaction, Miriam Kidron beneficially owns 1,568,222 shares of common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued executive alignment and retention, which is generally favorable for long-term company stability and strategic execution.

Positives

• The grant of 119,558 Restricted Stock Units to a key executive like the Chief Scientific Officer aligns management's interests with long-term shareholder value.
• Equity compensation can serve as a retention tool for critical personnel, ensuring stability in leadership.

Negatives

• The grant of RSUs, while common, represents potential future dilution for existing shareholders as these units convert to common stock over time.

Risks

• Future dilution from the conversion of Restricted Stock Units into common stock upon vesting.

Future Outlook

The vesting schedule for the Restricted Stock Units indicates a commitment to long-term executive retention and performance through April 2028, assuming 8 quarterly installments from April 2026.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through Restricted Stock Units, is a standard practice in the biotechnology and pharmaceutical sectors to incentivize and retain key scientific and executive talent. This grant to Oramed's Chief Scientific Officer is consistent with industry norms for aligning management interests with long-term company performance and shareholder value creation.

Stakeholder Impact

• Shareholders: Potential future dilution as RSUs convert to common stock, but also improved alignment of executive interests with long-term shareholder value.
• Employees: Signals continued commitment to executive compensation and retention strategies within the company.

Next Steps

• The granted RSUs will begin vesting in 8 quarterly installments starting April 1, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a key executive, which is an expected part of executive incentive programs. While it aligns management's interests with long-term shareholder value, it does not present new information that would fundamentally alter the investment thesis for Oramed Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate as this event alone does not warrant a change in investment position.

Keywords

Oramed Pharmaceuticals, ORMP, Miriam Kidron, Restricted Stock Units, RSU, Equity Compensation, Insider Transaction, Form 4, Chief Scientific Officer, Director